ArticleBMC medicine2025
LEAST as a novel prediction model of hepatocellular carcinoma development in patients with chronic hepatitis B: a multi-center study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlation between liver stiffness measurement and hepatocellular carcinoma risk: A case control study.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundConsidering the heavy burden on healthcare resources owing to HBV infection and the broad feasibility of transient elastography techniques in China, we aimed to construct and corroborate a liver stiffness measure (LSM)-dictated prediction model concerning hepatocellular carcinoma (HCC) development among CHB patients.
methodsA retrospective cohort study was conducted, involving 713 consecutive patients with CHB. These patients were randomly assigned to the derivation (n = 534) and internal validation (n = 179) cohorts, respectively. Variable selection was optimized using the least absolute shrinkage and selection operator (LASSO) regression and subsequent multivariate Cox regression analysis. A corresponding nomogram was built and compared regarding discrimination, calibration, and risk stratification across the whole population. To further verify the generalizability of the predictive model, we integrated data from multiple external centers to construct two external validation cohorts for evaluation (n = 1084 and n = 623).
resultsDuring a median follow-up duration of 57 months, 48 (8.99%) patients in the derivation cohort and 18 (10.06%) patients in the internal validation cohort developed HCC. Following the LASSO alongside Cox regression analyses, 5 variables were retained and constituted the LEAST model (LSM, age, albumin, sex, and platelet) and resulting nomogram. Our proposed model demonstrated sufficiently discriminative abilities to predict cumulative HCC development, as indicated by a time-dependent area under the curve (tdAUC) of 0.838 (95% CI 0.752-0.925), 0.898 (95% CI 0.851-0.944), and 0.907 (95% CI 0.856-0.959) over 3, 5, and 8 years, respectively. Nomogram-derived risk strata can appropriately identify patients at high risk of developing HCC. Our prediction model exhibited numerically the highest AUC compared to several previous scores. Moreover, the validity and generalizability of the LEAST model were verified in 2 independent external validation cohorts, confirmed in the calibration and stratification performance.
conclusionsThe LEAST model could predict HCC development in CHB patients, facilitating the identification of high-risk patients who might benefit from enhanced surveillance or early therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.